Industries > Pharma > Global Biosimilar Monoclonal Antibodies Forecast 2017-2027

Global Biosimilar Monoclonal Antibodies Forecast 2017-2027

Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

PUBLISHED: 19 May 2017
PAGES: 204
PRODUCT CODE: PHA0194

Clear
WOOCS 2.2.1

The global biosimilar monoclonal antibodies market is expected to grow at a CAGR of 9.6% in the second half of the forecast period. The market is expected to grow at a CAGR of 23.8% from 2015-2027. The market is estimated at $4.2bn in 2020 and $7.9bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 72 tables and 72 figures – all unavailable elsewhere.

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Biosimilar Monoclonal Antibodies Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound:
– Infliximab
– Rituximab
– Abciximab
– Trastuzumab
– Adalimumab
– Bevacizumab

• This report also shows revenue to 2027 for individual biosimilar mAb products in the market:
– Remsima/Inflectra
– Infimab
– Reditux
– BI695500
– CT-P10
– BI695501
– FKB327
– FKB238
– Mabtas
– AcellBia
– Maball
– Clotinab
– Abcixirel
– BCD-022
– BCD-021
– Herzuma
– CANMAB/Hertraz

• Our analyses show individual revenue forecasts to 2027 for these regional and national markets:
– The US Biosimilar mAb Market
– Japanese Biosimilar mAb Market
– EU5 Biosimilar mAb Markets
– BRIC and South Korea Biosimilar mAb Markets
– Rest of the World Biosimilar mAb Market

Global Biosimilar Monoclonal Antibodies Forecast 2017-2027

• This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline

• Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market

Visiongain’s study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.

Buy our report today Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Biosimilar Monoclonal Antibodies Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Biosimilar Monoclonal Antibodies Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

READ

Visiongain Publishes Inhalation & Nasal Spray Generic Drugs Market Report 2021-2031

Rising prevalence of chronic respiratory diseases including asthma, COPD, and allergic rhinitis; rising geriatric population, escalating investment in drug R&D by biopharmaceutical & pharmaceutical companies; growing respiratory health care awareness; and new product launches worldwide are some of the major factors that boosting the growth of global inhalation & nasal spray generic drugs market.

31 March 2021

READ

Categories